Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database

Background: MIBC is an aggressive disease, with 5-year survival rates ranging from 36 to 48% for p T3/p T4/p N+tumors. Perioperative treatment can improve overall survival, with more robust evidence in favor of neoadjuvant chemotherapy. Few randomized studies have compared neoadjuvant and adjuvant t...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Bene, Gabriella, Calabrò, Fabio, Giannarelli, Diana, Plimack, Elizabeth R., Harshman, Lauren C., Yu, Evan Y., Crabb, Simon J., Pal, Sumanta Kumar, Alva, Ajjai S., Powles, Thomas, De Giorgi, Ugo, Agarwal, Neeraj, Bamias, Aristotelis, Ladoire, Sylvain, Necchi, Andrea, Vaishampayan, Ulka N., Niegisch, Günter, Bellmunt, Joaquim, Baniel, Jack, Galsky, Matthew D., Sternberg, Cora N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252384/
https://www.ncbi.nlm.nih.gov/pubmed/30510914
http://dx.doi.org/10.3389/fonc.2018.00463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252384/
https://www.ncbi.nlm.nih.gov/pubmed/30510914
http://dx.doi.org/10.3389/fonc.2018.00463

Ejemplares similares